Company Analysis
Sign in

Organon & Co. (OGN)

NYSE: OGN · Pharmaceutical Preparations · Jersey City, NJ · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.4
◀ Past 6.6● Present 5.9▶ Future 3.6
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

129 patents granted to the 9 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Organon & Co.’s names, not what it holds today.

Patents granted
129
122 utility, 7 design, 1976 to Dec 31, 2025
Granted in 2025
5
Against 3 in 2024 and 7 in 2023
Applications published
176
6 of them in 2025
Names they are printed under
9
a subsidiary
By yearGrantedApplications published
'07'08'09'10'11'12'13'17'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals11
Medical technology8
Organic fine chemistry3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name9 counted
N.V.Organon a subsidiary
NL, as the owner printed on each patent. 3 more under the same name are not counted (printed in US)
101 granted
121 published
DERMAVANT SCIENCES GMBH a subsidiary
CH, as the owner printed on each patent
20 granted
14 published
Dermavant Sciences GmbH a subsidiary
named as the applicant on its applications, in CH
0 granted
20 published
Alydia Health, Inc. a subsidiary
US, as the owner printed on each patent
8 granted
2 published
ALYDIA HEALTH, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
9 published
Organon Ireland Ltd. a subsidiary
IE, as the owner printed on each patent
0 granted
4 published
Organon R&D Finland Ltd a subsidiary
named as the applicant on its applications, in FI
0 granted
3 published
Organon USA, Inc. a subsidiary
US, as the owner printed on each patent
0 granted
2 published
Organon Pharma (UK) Limited a subsidiary
GB, as the owner printed on each patent
0 granted
1 published
Names not counted (1)
Organon & Co.
Most of its patents print NL; this name counts in US. 2 granted and 0 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,458,399Postpartum uterine hemorrhage deviceMedical technologyAlydia Health, Inc.
May 20, 202512,303,168Uterine hemorrhage controlling system and methodMedical technologyAlydia Health, Inc.
May 6, 202512,290,285Uterine hemorrhage controlling system and methodMedical technologyAlydia Health, Inc.
Apr 15, 202512,275,696Process for preparing tapinarofOrganic fine chemistryDERMAVANT SCIENCES GMBH
Mar 18, 202512,252,471Isoquinoline compounds and their use in treating AhR imbalancePharmaceuticalsDERMAVANT SCIENCES GMBH
Sep 3, 202412,076,047Uterine hemorrhage controlling system and methodMedical technologyAlydia Health, Inc.
Mar 26, 202411,938,099Use of tapinarof for the treatment of atopic dermatitisPharmaceuticalsDERMAVANT SCIENCES GMBH
Mar 19, 202411,931,074Uterine hemorrhage controlling system and methodMedical technologyAlydia Health, Inc.
Nov 28, 202311,827,605Isoquinoline compounds and their use in treating AhR imbalancePharmaceuticalsDERMAVANT SCIENCES GMBH
Apr 11, 202311,622,945Topical pharmaceutical compositionsPharmaceuticalsDERMAVANT SCIENCES GMBH
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 11, 20252025/0282730ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCEPharmaceuticalsDERMAVANT SCIENCES GMBH
Aug 28, 20252025/0270158PROCESS FOR PREPARING TAPINAROFOrganic fine chemistryDERMAVANT SCIENCES GMBH
Aug 21, 20252025/0263431THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVESOrganic fine chemistryOrganon R&D Finland Ltd
Aug 7, 20252025/0248741UTERINE HEMORRHAGE CONTROLLING SYSTEM AND METHODMedical technologyALYDIA HEALTH, INC.
Jul 3, 20252025/0214938PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)-METHANOLOrganic fine chemistryOrganon Pharma (UK) Limited
Jun 19, 20252025/0195108UTERINE HEMORRHAGE CONTROLLING SYSTEM AND METHODMedical technologyALYDIA HEALTH, INC.
Nov 14, 20242024/0374288UTERINE HEMORRHAGE CONTROLLING SYSTEM AND METHODMedical technologyALYDIA HEALTH, INC.
Sep 26, 20242024/0315985REMITTIVE EFFECTS OF TAPINAROF IN THE TREATMENT OF PLAQUE PSORIASIS, ATOPIC DERMATITIS, OR RADIATION DERMATITISPharmaceuticalsDERMAVANT SCIENCES GMBH
Sep 19, 20242024/0309043THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVESOrganic fine chemistryOrganon R&D Finland Ltd
Aug 29, 20242024/0285550TOPICAL PHARMACEUTICAL COMPOSITIONSPharmaceuticalsDERMAVANT SCIENCES GMBH
What it applied for, 2024 to 2025: Organic fine chemistry 5 · Pharmaceuticals 4 · Medical technology 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton OGN · research, not advice